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Abstract
p130Cas adaptor protein regulates basic processes such as cell cycle control, survival and migration. p130Cas over-
expression has been related to mammary gland transformation, however the in vivo consequences of p130Cas over-
expression during mammary gland morphogenesis are not known. In ex vivo mammary explants from MMTV-p130Cas
transgenic mice, we show that p130Cas impairs the functional interplay between Epidermal Growth Factor Receptor (EGFR)
and Estrogen Receptor (ER) during mammary gland development. Indeed, we demonstrate that p130Cas over-expression
upon the concomitant stimulation with EGF and estrogen (E2) severely impairs mammary morphogenesis giving rise to
enlarged multicellular spherical structures with altered architecture and absence of the central lumen. These filled acinar
structures are characterized by increased cell survival and proliferation and by a strong activation of Erk1/2 MAPKs and Akt.
Interestingly, antagonizing the ER activity is sufficient to re-establish branching morphogenesis and normal Erk1/2 MAPK
activity. Overall, these results indicate that high levels of p130Cas expression profoundly affect mammary morphogenesis by
altering epithelial architecture, survival and unbalancing Erk1/2 MAPKs activation in response to growth factors and
hormones. These results suggest that alteration of morphogenetic pathways due to p130Cas over-expression might prime
mammary epithelium to tumorigenesis.
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Introduction
p130Cas, originally identified as a highly phosphorylated
protein in cells transformed by v-Src and v-Crk oncogenes, is a
multifunctional adaptor protein required for embryonic develop-
ment [1] and is characterized by structural motifs that enable
interactions with a variety of signaling molecules. These multi-
protein complexes sense and integrate signaling originating from
several receptor systems [2]. In normal cells, p130Cas modulates
cell motility, survival and proliferation [3]. p130Cas is emerging as
an important player in the transformation and invasion driven by
different oncogenes [4,5]. In particular, we have previously shown
that p130Cas accelerates mammary tumor formation and
progression in the presence of ErbB2 [6,7]. Moreover, it has been
shown that patients with primary breast tumors expressing high
levels of p130Cas (also known as BCAR-1) experience a more
rapid disease recurrence and have a greater risk of resistance to
tamoxifen therapy [8]. In addition, we have shown that in
estrogen-dependent T47D breast cancer cells, p130Cas associates
to the estrogen receptor alpha to form a macromolecular complex
containing c-Src kinase, Crk, and p85 subunit of phosphatidyli-
nositol 3-kinase (PI3K) and mediates non genomic estrogen
signaling [9]. However, few data are addressing the in vivo role of
p130Cas in the mammary gland development. We have demon-
strated in a MMTV-model of transgenic mice that the over-
expression of p130Cas affects mammary gland development by
inducing epithelial cell hyperplasia during pregnancy and lactation
and delayed involution [10]. Nevertheless, neither functional nor
mechanistic data on the role of p130Cas during hormonal and
growth factors driven mammary gland morphogenesis have been
reported.
At birth, the mammary gland consists of a simple ductal
network that fills a fraction of the mammary fat pad and remains
quiescent until puberty when steroid and pituitary hormones, local
growth factors and cytokines, stimulate branching morphogenesis
by inducing rapid proliferation and expansion of this primitive
mammary network [11,12]. The mammary tree expansion is
driven by the terminal end-buds (TEBs) which are clover-shaped
structures that encapsulate the tips of primary ducts. As primary
ducts elongate, bifurcation (or primary branching) of the TEBs
generates additional primary ducts, which in turn are subjected to
lateral secondary branching, leading to tertiary lateral branches
that occur at each diestrus and during pregnancy. When the
extremities of the fat pad are reached, the end-buds shrink in size
and become mitotically inactive, completing the pubertal growth
phase [13]. The very complex process of branching morphogen-
esis is regulated by a wide range of factors expressed in the
epithelium or stroma, such as epidermal growth factor (EGF),
amphiregulin, hepatocyte growth factor (HGF) and fibroblast
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growth factor (FGF) [14,15]. In addition, hormones including
estrogen, progesterone, glucocorticoids, and retinoids have also
been implicated in the development and maintenance of
mammary epithelial structures [14,16]. It has been shown that
growth factors and hormones work in concert with each other to
promote ductal morphogenesis in vivo [17]. Consistently, growth
factor receptors such as Epidermal Growth Factor Receptor
(EGFR) and Fibroblast Growth Factor Receptor (FGFR) families
and estrogen receptor (ER) have been described to be crucial for
normal mammary development [18,19,20,21]
To examine the interplay between p130Cas, growth factor and
estrogen signals, and mammary branching morphogenesis we
choose, as experimental model, an organotypic 3D mammary
primary culture that mimics aspects of mammary branching
morphogenesis in vivo [22]. We demonstrated that p130Cas over-
expression in presence of the concomitant stimulation with
estrogen and EGF leads to aberrant mammary morphogenesis
with the appearance of multicellular spherical filled structures
characterized by impaired cell architecture and increased survival.
The aberrant branching is supported by hyper-activation of Erk1/
2 MAPKs and Akt signaling that is mainly dependent on ER. Our
data indicate that during mammary morphogenesis, high levels of
p130Cas expression can enforce EGFR/ER-induced proliferation
and survival pathways that are hallmarks for cell transformation.
Materials and Methods
Mice
The use of animals was in compliance with the Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the University
of Torino on May 18th, 2011. All efforts were made to minimize
animal suffering.
MMTV-p130Cas transgenic mice have been previously de-
scribed [10]. Two independent MMTV-p130Cas transgenic lines
were used (line 25 and line 37).
Antibodies
Polyclonal antibodies to phospho-Erk1/2 MAPK (Thr202/
Tyr204), phosphor-Src (Tyr416), phospho-p130Cas (Tyr410),
p130Cas, Erk1/2 MAPK, phosphoAkt (S473) and Akt were
purchased from Cell Signaling (Danvers, MA, USA). Antibodies
against cleaved caspase-3 were from Millipore (Billerica, MA,
USA). Antibodies against c-Src, Erk1/2, vinculin and tubulin from
Santa Cruz (Palo Alto, CA, USA). Mouse monoclonal antibodies
anti-Ki67 were from Novocastra, (Leica Microsystem, Germany),
rabbit polyclonal antibodies anti-K14 from Covance (Pinceton,
NJ, USA) and mouse monoclonal anti-keratin18 (K18) from
(Progen, Heidelberg, Germany).
Isolation of primary mammary organoids
4th inguinal mammary glands were removed from 12 week-old
virgin FVB-MMTV-p130Cas and wt littermates and minced.
Minced tissue was incubated at 37uC for 40 minutes in a
collagenase/trypsin mixture (0.25% trypsin-EDTA) (Gibco,
Grand Island NY, USA), 0.2% collagenase type IV (Roche
Applied Science, IN) in phenol red-free DMEM-F12 (Gibco) with
5% charcoal fetal bovine serum (Gibco Grand Island NY, USA),
5 ng/ml insulin, 50 ng/ml gentamicin, and 1% penicillin/
streptomycin (Gibco) (basal medium). In order to isolate the
epithelial content from the fat, the suspension obtained after
digestion was centrifuged three times at 1500 rpm for 10 minutes
and the supernatant was recovered. The final pellet was
resuspended in Matrigel Phenol Red Free Growth Factor Reduced
(BD Transduction Laboratories, Franklin Lakes, NY).
Morphogenesis assays and Analysis of branching
morphogenesis
Primary organoids were mixed in Matrigel and added to a 96-
well containing an underlay of 25 ml of solidified Matrigel. Basal
medium (phenol red-free DMEM-F12) supplemented with 35 ng/
ml of Epidermal Growth Factor (EGF) or basic Fibroblast Growth
Factor (FGF) (both from Sigma (St Louis, MI, USA)) and with or
without 10 nM 17b-estradiol (E2) (Tocris, Park Ellisville, MO,
USA) were added to the wells. Every other day, medium of all
samples was replenished. The branching phenotype of organoids
was determined after cultivation for 4–5 days. A branching
phenotype was defined as an organoid having at least two
branches extending from its central body, whereas secondary
branching was defined as branches coming out from primary
branches. Brightfield microscope images were acquired using the
Axio Observer Z1 microscope (Zeiss, Germany). Pharmacological
inhibitors for EGFR (1 mM AG1478, Sigma, St Louis, MI, USA),
Estrogen Receptor (100 nM ICI 182,780, Tocris) and Erk1/2
MAPK (2 mM PD98059, Sigma, St Louis, MI, USA) were added
to basal medium with or without EGF and 17b-estradiol stimuli
24 hours after plating and medium was replaced every other day.
Branching response was evaluated after 4–5 days of culture as
described above.
Quantification of branching was carried out by counting the
percentage of branching in each well (50–100 organoids/well) All
experiments were carried out at least in triplicates in at least 4
independent experiments.
Organoids stimulation, protein extraction, SDS-Page and
western blotting analysis
Phosphorylation kinetics of Erk1/2 MAPKs, Akt and c-Src were
evaluated by adding growth factor/17b-estradiol supplemented
medium for different time points. For inhibition of EGFR, ER and
MAPK signaling, organoid cultures were left without stimuli for
24 hours followed by the addition of 1 mM AG1478, 100 nM ICI
182,780 and 2 mM PD98059 to basal medium for 1 hour at 37uC.
For protein extraction, media were removed and organoids were
washed once with cold PBS plus phosphatase inhibitors (NaVO4,
1 mM and NaF 1 mM) (Sigma, St Louis, MI, USA), and treated
with the Cell recovery solution (BD Transduction laboratories,
Franklin Lakes, NY) for 25 minutes at 4uC. The suspension
obtained was centrifuged at 500 g for 5 minutes at 4uC.
Supernatant was discarded and pellet containing organoids was
then treated with a lysis buffer (2% SDS, 5 mM EDTA, 1 M Tris
HCl pH 7.5) supplemented with protease inhibitor cocktail (Roche
Applied Science, IN) and phosphatase inhibitors: 10 mM NaF,
1 mM sodium vanadate and 10 mM PMSF (Sigma, St Louis, MI,
USA). Cell lysates were separated on 8% SDS-polyacrylamid gels
and western blotting was performed.
Immunofluorescence analysis
Immunofluorescence analysis was performed as described in
Fata et al. (2007). Briefly, for detection of keratin-14 (K14),
keratin-18 (K18) and Ki67, organoids were treated with a 18%
sucrose solution in PBS for 15 minutes at RT followed by a
15 minute treatment with 30% sucrose in PBS at RT. After
sucrose treatments, organoids were gently pipetted up and down
and smeared onto a glass slide. Smeared organoids were air dried
for 2 hours at RT and then fixed in methanol:acetone (1:1 v/v) for
10 minutes at 220uC. After fixation slides were air-dried at RT
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for 2 hours followed by blocking in 10% goat serum in PBS for
1 hour at RT. Primary antibodies were incubated in blocking
buffer overnight at 4uC, followed by 3 washes of 15 minutes each
in 0.5% Triton-X in PBS. Alexa dyes-coniugated secondary
antibodies (Molecular Probes, Invitrogen) were used at 1:1000
dilutions. To visualize DNA, fixed cells were stained with 49,6-
diamidino-2-dhenylindole (DAPI; Sigma). Images were captured
by a HCX PL APO CS 6361.4 OIL Leica TCS-SP5 II confocal
microscope and analyzed with LASAF software (Leica, Germany).
TUNEL assay
For the analysis of apoptotic cells, fragmentation of DNA in
populations of cells in organotipic cultures was detected by using
the in situ cell death detection kit TMR protocol (Roche Applied
Science, IN). Briefly, after fixation of organoids as described
above, smeared organoids onto glass slide were washed twice with
PBS and samples were permeabilized with Triton 0.5% for
2 minutes on ice. Organoids were washed 3 times with PBS, and
incubated with the TUNEL-reaction mixture (Roche Applied
Science, Indianapolis, IN, USA) for 60 minutes at 37uC.
Additional PBS washes were done before the analysis of the
samples by fluorescence microscopy. Images were acquired using
an ApoTome system (Zeiss, Germany).
Statistical analyses
Statistical significance was determined with two tailed Student’s
t-test with error bars representing standard error of the mean
(SEM). Statistical significance was also evaluated by using Anova
two-way test. p,0.05 (*) p,0.001 (**).
Results
p130Cas expression enhances EGF-mediated branching
morphogenesis in mouse primary organoids
We have previously shown in a MMTV transgenic model that
p130Cas over-expression in the mammary gland leads to
hyperplasia of the mammary epithelium during pregnancy and
lactation and to delayed involution [10]. However, the role of
p130Cas during the early phases of mammary gland development
is still unknown. To address this point, we first evaluated the levels
of expression of p130Cas in physiological conditions by perform-
ing real-time reverse transcriptase PCR (qPCR) on total RNAs
isolated from wt primary mammary epithelial cells of FVB mice at
different times during puberty. The results indicate that the levels
of p130Cas mRNA in the wt mammary gland peaks during
puberty at 6 weeks of age (Fig. 1A, right panel), suggesting a
biological role for p130Cas in pubertal mammary development in
virgin mice. Consistently, p130Cas protein also show a similar
trend of expression at the same developmental stages (Fig. 1A, left
panel). To explore the mechanism implicating p130Cas during
branching morphogenesis, we prepared organotypic 3D mamma-
ry primary cultures from MMTV-p130Cas transgenic mice. This
culture model mimics aspects of mammary branching morpho-
genesis in vivo and is responsive to growth factors and hormones
produced in the mammary gland [22]. Mammary gland organoids
were isolated from 12 week old wt and p130Cas-MMTV
transgenic mice and allowed to grow in matrigel. At this age,
high yield organoid preparations can be easily obtained [22] and
p130Cas protein expression is elevated. p130Cas expression was
evaluated in wt and transgenic organoids and, as expected, it was
about 2.5 fold higher in p130Cas organoids (p130Tg) compared to
the wt (Fig. 1B, upper and lower panels). Mammary branching
was induced by stimulating the cell culture with FGF-2 and EGF,
two growth factors implicated in the local control of postnatal
mammary development [11,15,20,21,23], for the indicated days
(Fig. 1C). Interestingly, the over-expression of p130Cas itself did
not affect mammary branching (Fig. S1A). Conversely, the
addition of EGF and FGF-2 led to an altered morphogenetic
response in p130Tg organoids characterized by a strong increase
in primary and secondary branching at 4 and 5 days (Fig. 1C,
panels e, f, m, n) compared to wt organoids (Fig. 1C, panels c, d, h,
i). Specifically, as a measure of the morphogenetic response, we
counted the relative number of organoids with primary and
secondary branching, regardless of their size, and we showed that
p130Tg organoids at 5 days of culture show a 3 fold increase in the
morphogenetic response upon EGF stimulation and a 2.3 fold
increase upon FGF-2 stimulation compared to the wt (Fig. 1D).
These results ex-vivo support the involvement of p130Cas during
growth-factor dependent branching morphogenesis.
p130Cas over-expression impairs branching
morphogenesis of mammary organoids in response to
estrogen and EGF stimulation
In the pubertal mammary gland, the initial driving force for
ductal morphogenesis comes from circulating ovarian and
pituitary hormones. In particular, there are critical requirements
for estrogen during ductal morphogenesis [14,16,24]. Moreover,
p130Cas scaffold protein has been described as a highly dynamic
component of the estrogen receptor signaling complex and plays a
crucial role in the early steps of estrogen-dependent non-genomic
signaling in breast cancer cells [9]. Therefore, we assessed whether
high levels of p130Cas upon estrogen stimulation affect mammary
gland development. Morphogenesis of wt and p130Cas organo-
typic cultures was evaluated in the presence of estrogen alone (E2)
and in combination with growth factors. The addition of E2 in the
primary cultures did not alter the morphogenetic response
regardless of p130Cas over-expression (Fig. 2A, panels c–d).
Surprisingly, upon the concomitant stimulation with E2 and EGF,
the over-expression of p130Cas promoted a unique phenotype
characterized by the presence of spherical epithelial structures
(Fig. 2A, panel h) whereas in wt organoids branching morpho-
genesis normally occurred (panel h). This was not due to an altered
p130Cas protein expression upon E2, EGF and EGF+E2
treatments (Figure S1B). The transgenic phenotype was specific
for the concomitant stimulation with E2 and EGF in presence of
p130Cas, since branching morphogenesis was not affected in
E2+FGF-2 stimulated organotypic cultures in both wt and p130Tg
organoids (Fig. 2A, panels m,n). The quantitative analysis of the
branching response indicated that the concomitant addition of
EGF and E2 promoted primary and secondary branching in wt
but not in p130Tg organoids where the formation of enlarged
spherical epithelial structures was evident in approximately 50% of
the organoids (Fig. 2B). These enlarged spherical structures were
about four fold bigger compared to not-branched acinar structures
observed in untreated wt and p130Tg organoids and in not
branched EGF+E2 treated wt organoids (Fig. 2C). These data
show that high levels of p130Cas in presence of EGF and E2
stimulation severely alters mammary gland morphogenesis leading
to a specific phenotype characterized by absence of branching.
Moreover, this altered morphogenesis is driven by combined E2
and EGF stimulation, suggesting that p130Cas preferentially
interferes with responses generated by EGFR and ER rather than
FGFR and ER.
p130Cas in Mammary Branching Morphogenesis
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p130Cas-overexpression leads to impairment of
epithelial architecture and luminal clearance in response
to E2 and EGF treatment
To determine whether the aberrant branching phenotype
observed in the organoids isolated from the p130Tg mice was
due to alterations in polarization and luminal cavitation, we
performed immunofluorescence analysis by using antibodies
against K14 and K18, which detect myoepithelial and luminal
epithelial cells, respectively. Fluorescence microscopy analysis of
K14 and K18 immunostaining after 4 days of culture (Fig. 3A)
showed that untreated wt and p130Tg organoids preserved a basal
layer of K14-positive myoepithelial cells and an inner layer of
K18-positive luminal epithelial cells, a localization that resembles
the in vivo mammary epithelial architecture (Fig. 3A, a–b). Wt and
p130Tg organoids that have undergone EGF-dependent branch-
ing morphogenesis had similar spatial arrangement characterized
by myoepithelial cells surrounding an inner luminal layer with
developing branches and central lumen (Fig. 3A, c–d and Fig. S2).
Strikingly, upon the concomitant addition of E2 and EGF,
p130Tg organoids display a disorganized localization of K14-
positive myoepithelial cells that were often present within the inner
K18-positive cell layer (Fig. 3A, panel h and Figure S2) in contrast
to wt-organoids that retained the bilayer organization of myoepi-
thelial-luminal cells (Fig. 3A, panel g and Figure S2). To determine
Figure 1. Effects of p130Cas expression on branching morphogenesis in primary mouse mammary gland organoids grown in 3D
Matrigel cultures. (A) Let panel: qRT-PCR expression analysis of p130Cas using total RNA isolated from the 4th inguinal mammary gland of at least
three FVB wt mice during different stages of puberty. The amount of p130Cas mRNA was normalized to 18S rRNA. Right panel: Analysis of p130Cas
protein expression from wt mice (three mice/stage) at the same stages of puberty as in the left panel. (B) Analysis of p130Cas protein expression from
5 day untreated wt and p130Tg organoids (upper panel) and quantification analysis expressed as the mean of p130Cas/tubulin 6 standard deviation
(SD) (*p,0.05) (lower panel). (C) Brightfield images of representative wt and p130Tg organoids, after 1, 4 and 5 days of culture in presence of EGF
(35 ng/ml) or FGF-2 (35 ng/ml) in the culture medium. Images were captured by using the Axio Observer Z1 microscope. (D) Quantitative analyses of
branching morphogenesis after treatment of wt and p130Tg organoids with EGF and FGF-2 at 5 days. The plot represents the mean number of
overall branching response in at least three wells from 4 independent experiments. Similar results were obtained with a second p130Cas transgenic
line (data not shown). Quantification of the mean number of branched organoids buds was significantly higher in EGF and FGF-2 treated p130Tg
organoids compared to wt organoids (*p,0.002).
doi:10.1371/journal.pone.0049817.g001
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whether this altered architecture was due to defects in lumen
cavitation, cells from EGF2, EGF+E2-treated and from untreated
wt and p130Tg organoids were immunostained with the nuclear
marker DAPI and confocal microscopy images of z-stack were
analyzed (Fig. 3B). The presence of the lumen was clearly visible in
wt and p130Tg untreated organoids (Fig. 3B, first two rows, white
arrows) and in EGF or EGF+E2-treated wt organoids (Fig. 3B, 3rd
and 5th rows, white arrows). In contrast in p130Tg mammary
organoids the lumen was partially filled upon EGF (Fig. 3B, 4th
row, white arrowhead) or completely filled upon EGF+E2 (Fig. 3B,
6th row, white arrowhead) stimulation. Thus, these data demon-
strate that during EGF-branching morphogenesis p130Cas over-
expression affects myoepithelial and luminal epithelial cell
localization and that the concomitant stimulation with E2 leads
to impairment of branching morphogenesis characterized by
inhibition of lumen cavitation.
Figure 2. Effects of E2 stimulation on EGF2 and FGF-dependent branching morphogenesis. (A) Brightfield images of representative wt
and p130Tg organoids, cultured for 5 days in the absence or presence of E2, EGF, or the combination of both. (B) Quantification of primary and
secondary branching of wt vs. p130Tg organoids upon treatment with either E2, EGF or EGF+E2 for 5 days. Experiments were repeated at least five
times. Two-way ANOVA analysis show a significant effect of both treatment (EGF vs. EGF+E) and genotype (wild type vs. transgenic) for Acinar
Structures, secondary branching and enlarged spheroids (P,0.0001 for both treatment and genotype). For primary branching only treatment has a
significant effect (P,0.0001). Interaction between treatment and genotype is significant for all variables (Acinar: P,0.0065; primary branching:
P,0.0001; secondary branching: P,0.0001; enlarged spheroids: P,0.0001). (C) Quantification of spherical organoids size in untreated and EGF+E2
treated wt and p130Tg organoids was performed by using ImageJ software. Statistical significance is indicated (** p,0.001).
doi:10.1371/journal.pone.0049817.g002
p130Cas in Mammary Branching Morphogenesis
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p130Cas alters cell survival in EGF+E2-treated mammary
organoids
An essential role for apoptosis during lumen formation has been
previously established by using a non-tumorigenic human
mammary epithelial cell line MCF10A which forms organized
structures with hollow central lumens when grown in a 3D matrix
[25]. In vivo, the mammary gland primary ducts behind the TEBs
are characterized by a single layer of luminal epithelial cells
surrounding an empty hollow lumen. The body cells that border
the TEB and the luminal space possess high rates of apoptosis,
which contrasts with the low apoptotic rates observed in cap cells
at the distal end of the developing duct, suggesting that apoptosis
of body cells may contribute to lumen formation [26]. Moreover,
proliferation-dependent mechanisms that control lumen size have
been described [26] and the role of p130Cas in cell survival and
proliferation has been established in various in vitro and in vivo
models [5]. Therefore, we assessed whether the impairment of
mammary branching and lumen formation observed in the
EGF+E2-treated p130Tg organoids was dependent on an
aberrant proliferation and/or apoptosis rate. We evaluated
proliferation levels in wt and p130Tg organoids by performing
Ki67 immunostaining at 2 days of culture. While, there were no
differences in cell proliferation between E2 treated wt and p130Tg
organoids (Fig. 4A), cell proliferation was induced in EGF2 and
EGF+E2-treated wt and further induced in p130Tg organoids.
The quantitative analyses of these data indicate that the extent of
cell proliferation was slightly increased (p,0.02) in EGF+E2-
treated p130Tg organoids compared to EGF+E2-treated wt
organoids, thus indicating that the increased proliferation might
contribute at least in part to altered branching. Therefore, we
evaluated whether the alteration in branching morphogenesis
observed was also due to differences in cell survival. As shown in
Figure 4B (upper panel), at day 2 of culture, p130Cas over-
expressing organoids in presence of EGF+E2 showed a marked
decrease in the levels of cleaved caspase-3 compared to wt
organoids. Significant differences in the cleavage of caspase-3 were
also observed at day 5 of culture (lower panel). To further support
this observation, we performed TUNEL analyses at day 2 of
culture (Fig. 4C, left panel and right panel). TUNEL-positive
nuclei were increased in both EGF treated wt and p130Tg
Figure 3. E2 treatment of p130Tg organoids alters myoepithelial-luminal architecture and lumen clearance. (A) Confocal images
representing immunofluorescence staining for K14 (red; myoepithelium) and K18 (green; luminal epithelium) of wt and p130Tg organoids stimulated
with EGF and E2 at day 5 of culture. Scale bar = 0,50 micron. (B) Confocal z-stacks of DAPI staining of wt and p130Tg organoids at day 5 of culture to
visualize lumen clearance. Images in A and B were acquired using a Leica TCS-SP5 II confocal microscope. Images in A and B are representative of four
independent experiments.
doi:10.1371/journal.pone.0049817.g003
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organoids (Fig. 4C, panels b and e), whereas addition of E2 did not
affect apoptosis (data not shown). Consistently with cleaved
caspase 3 levels, in presence of concomitant stimulation with
EGF+E2, the number of TUNEL positive nuclei was strongly
reduced in p130Tg compared to wt organoids (Fig. 4 panels c and
f). Overall, these data indicate that p130Cas over-expression at
early times of culture protects from apoptosis in presence of E2
and EGF stimulation.
p130Cas over-expression leads to Erk1/2 MAPK and Akt
hyperactivation in response to EGF+E2 treatment of
primary mammary organoids
Since extracellular signal regulated kinase 1/2, mitogen-
activated protein kinases (Erk1/2 MAPK) have been described
to be master regulator of mammary gland morphogenesis by
controlling both cell proliferation and apoptosis [22], we asked
whether p130Cas over-expression was affecting their activation in
response to E2 and EGF in the mammary organotypic model.
After 2 days of culture both wt and p130Tg organoids were
Figure 4. p130Cas over-expression enhances cell proliferation and survival in EGF and EGF+E2-treated primary organoids. (A)
Quantification of nuclear Ki67 staining from total nuclei count of each organoid at day 2. Quantification analysis of Ki67 staining as mean of Ki67
positive cells/total number of cells 6SD and significance are reported (*p,0.05, **p,0.001). More than 20 organoids from each condition were
counted in three independent experiments. (B) Western blot analysis of cleaved caspase-3 from 2 and 5 day of EGF, E2 and EGF+E2-treated wt and
p130Tg cultured organoids. Quantification analysis at day 2 and day 5 of cleaved-caspase 3 are reported on the right (*p,0.05). (C) TUNEL analysis
from 2 day treated wt and p130Cas cultured organoids. TUNEL positive cells in the organoids are stained in red. The plot represents the quantification
of the results of three independent experiments in which apoptotic cells are counted and normalized to the total number of nuclei/organoid for at
least 10 organoids from each condition 6 standard deviation (*p,0.05).
doi:10.1371/journal.pone.0049817.g004
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stimulated at the indicated times with EGF, E2, and EGF+E2
(Fig. 5A). Biochemical analysis of protein extracts of wt and
p130Tg organoids showed that in p130Cas over-expressing
organoids, EGF enhances Erk1/2 MAPKs phosphorylation levels
compared to wt (Fig. 5A). Interestingly, the concomitant treatment
with EGF and E2 led to a further Erk1/2 MAPKs activation in
p130Cas-Tg with respect to wt organoids (Fig. 5A). Quantification
of Erk1/2 MAPKs activation at 5, 30 minutes and 1 hour of
stimulation is shown in Fig. 5B. Overall, these data show that high
levels of p130Cas in mammary organoids result in increased levels
and duration of Erk1/2 MAPKs activation. Our data show that
Erk1/2 MAPKs activation observed in EGF+E2 is not dependent
by differential activation of c-Src (Fig. 5A) and p125Fak or on
EGFR stability between p130Tg and wt organoids (data not
shown). These data indicate that the EGFR/Src/Fak axis does not
correlate with Erk1/2 MAPKs hyperactivation.
To further characterize the signaling pathways that might
contribute to both proliferation and apoptosis, we evaluated the
activation of Akt, as the PI3K/Akt pathway has been described to
be stimulated by both EGF and estradiol in breast cancer cells
[27,28]. Wt and p130Tg were cultivated for 2 days and stimulated
as described above. While in EGF-treated p130Tg organoids Akt
activation peaks at 5 minutes and then decreases, in E2 and
EGF+E2-treated p130Tg organoids Akt activation is strongly and
significantly enhanced and sustained compared to wt organoids
(Fig. 5C and D). These data indicate that p130Cas over-expression
leads to a synergistic effect of EGF and E2 on Akt activation.
Taken together, these results indicate that both proliferative and
survival pathways are strongly activated in EGF+E2-treated
p130Tg compared to wt organoids.
ER-dependent Erk1/2 MAPK activation levels are
determinant for p130Cas-mediated branching
morphogenesis
To understand which signaling pathways is specifically involved
in the p130Cas-dependent alteration of Erk1/2 MAPKs activa-
tion, wt and p130Tg organoids were treated with ER antagonist
(ICI 182,780) or EGFR inhibitor (AG1478). Specifically, wt and
p130Tg organoids at 2 days of culture were pre-treated with ICI
182,780 and AG1478 for 1 hour prior to 5 minutes of EGF or
EGF+E2 stimulation. Protein extracts were analyzed for Erk1/2
MAPKs phosphorylation levels (Fig. 6A) and quantitative analysis
was performed (Fig. 6A and 6B). The inhibition of EGFR activity
in both wt and p130Tg organoids decreased Erk1/2 MAPKs
activation to levels comparable to untreated organoids (Fig. 6A
and 6B). Interestingly, interfering with ER signaling in wt
organoids did not affect substantially Erk1/2 MAPKs activation
upon EGF and EGF+E2 treatment. In contrast, ER inhibition in
p130Tg organoids reduced in both conditions Erk1/2 MAPKs
activity to levels similar to those observed in wt organoids (Fig. 6A,
B). These data indicate that Erk1/2 MAPKs increased activity
observed in p130Cas over-expressing organoids depends on ER
stimulation. Since it has previously demonstrated that antagoniz-
ing ER activity by prolonged tamoxifen treatment stimulates
adhesion dependent p130Cas tyrosine phosphorylation in breast
cancer cell lines [29], we checked whether treatment with ICI 182,
780 and AG1470 affects p130Cas phosphorylation status. As
shown in Figure S3, p130Cas phosphorylation levels were not
affected by ICI 182,780. To address whether the re-establishment
of the Erk1/2 MAPK activity to normal level following ER
inhibition is sufficient to rescue branching morphogenesis in
p130Tg organoids, we inhibited ER, EGFR, and Erk1/2 MAPKs
in organoids and we evaluated the morphological outcome after 5
days of culture in the presence of EGF+E2 (Fig. 6C). The results
showed that in both wt and p130Tg EGF2 and EGF+E2-treated
organoids, branching morphogenesis was completely blocked by
MAPK and EGFR inhibition by using PD98059 and AG1478
(Fig. S4). ER inhibition by ICI 182,780 treatment led only to a
slight reduction in branching in EGF or EGF+E2 treated wt
organoids (Fig. 6C, compare panel b to h and c to i). Interestingly,
in p130Tg organoids, the inhibition of ER in the presence of
EGF+E2 abrogated the formation of enlarged multicellular
epithelial spheroids re-establishing mammary branching (Fig. 6C,
compare panel n to f). The quantitative analysis of the branching
response indicated that ER inhibition by ICI 182,780 in presence
of EGF+E2 stimulation rescued primary and secondary branching
in p130Tg organoids to an extent that is similar to the
EGF2stimulated 130Tg organoids (Fig. 6D). Overall, these data
clearly show that p130Cas-dependent ER signaling impinges on
Erk1/2 MAPKs activation levels impairing proper branching
morphogenesis. Notably, re-establishing proper Erk1/2 MAPKs
activity is sufficient to revert p130Cas-dependent aberrant
branching morphogenesis.
Discussion
Here, by taking advantage of mammary organoids, a physio-
logically relevant 3D model for studying mammary morphogenesis
[22], we demonstrate the involvement of p130Cas in this process.
The initial observation that during mammary development
p130Cas expression peaks at 6 weeks of age and remains elevated
during puberty, prompted us to investigate the role of p130Cas
over-expression in mammary morphogenesis. Our results show
that high levels of p130Cas expression during puberty enhances
EGF-dependent mammary branching providing the first evidence
of the involvement of this adaptor protein in this physiological
process. As mentioned above, mammary morphogenesis is strictly
dependent during puberty on growth factors and hormones
stimulation [15]. Interestingly, upon the concomitant stimulation
of EGF and E2, p130Cas over-expression dramatically affects
mammary branching leading to the formation of enlarged
spheroids with filled lumen, absence of branching, increased
survival and hyper-activation of Erk1/2 MAPKs and Akt. In these
conditions, interfering with ER activity is sufficient to re-establish
normal branching, Erk1/2 MAPK indicating that p130Cas is a
crucial regulator of ER and growth factor signaling during
mammary morphogenesis.
The aberrant spheroids structures observed in p130Cas over-
expressing organoids show an altered architecture, an increased
survival as demonstrated by TUNEL analysis and cleaved caspase
3 expression. Several studies have pointed out the crucial role of
apoptosis during the lumen formation [30,31]. Moreover, it has
been demonstrated that the lack of survival signals from ECM can
trigger anoikis [32,33] both in vivo in animal models and in 3D
culture in vitro and that aberrant activation of growth factor
receptors and hormone receptors can disrupt ductal architecture
resulting in filling of the luminal space [25]. However, very little is
known about the molecular mechanisms that disrupt normal
ductal organization of epithelial cells. On the basis of our data, we
can speculate that the decreased apoptosis observed in p130Cas
over-expressing organoids can be due to the ability of p130Cas to
convey multiple survival signaling originating from Extracellular
Matrix, EGFR and ER [5]. Specifically, in branching morpho-
genesis, high levels of p130Cas coordinates and amplify survival
signals originated from both ER and EGFR that ultimately lead to
impairment of lumen formation.
Our data also indicate that in presence of high levels of p130Cas
upon EGF and E2 stimulation, a hyper-activation of Erk1/2
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MAPKs and Akt occurs. It has been previously reported that
sustained levels of Erk1/2 activation upon TGF alpha rather than
FGF7 stimulation, play a crucial role during pubertal mammary
gland development and branching, suggesting that the mammary
epithelium responds to multiple and concomitant growth factor
signals by finely temper the extent and the duration of the MAPKs
Figure 5. EGF+E2 treatment leads to Erk1/2 MAPKs and Akt hyperactivation in p130Tg organoids. (A) Western blot analysis of phospho-
Erk1/2 MAPKs in wt or p130Tg organoids stimulated with EGF and EGF+E2 at the indicated times. Vinculin and total Erk1/2 MAPKs blots are provided
as loading controls. Blots are representative of five independent experiments. (B) Quantification analysis of Erk1/2 MAPKs activation following
stimulation for 5, 30 minutes and 1 hour. Data are represented as the mean of phospho-Erk1/2 MAPK levels/total Erk1/2 MAPK 6 standard deviation
(SD) of five independent experiments (*p,0.05). (C) Western blot analysis of phospho-Akt in wt or p130Tg organoids stimulated as in (A). Total Akt
blots are provided as loading controls. Blots are representative of three independent experiments. (D) Quantification analysis of Akt activation
following stimulation as in (A). Data are represented as the mean of phospho-Akt levels/total Akt 6 standard deviation (SD) of three independent
experiments (*p,0.05).
doi:10.1371/journal.pone.0049817.g005
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Figure 6. Inhibition of ER activity in EGF+E2-treated p130Tg mammary organoids prevents Erk1/2 MAPK hyper-activation and
rescues branching morphogenesis. (A) Western blot analysis of phospho-Erk1/2 MAPKs in wt or p130Tg organoids pre-treated for 1 hour with ICI
182,780 or AG1478 followed by 5 minutes of EGF or EGF+E2 stimulation. Vinculin and total Erk1/2 MAPKs blots are provided as loading controls. Blots
are representative of three independent experiments. (B) Quantification analysis of Erk1/2 MAPKs activation of wt and p130Tg organoids pre-treated
for 1 hour with ICI 182,780 or AG1478 followed by 5 minutes of EGF or EGF+E2 stimulation is shown. Data are represented as the mean of the ratio of
phospho-Erk1/2 MAPK and total Erk1/2 MAPK levels6 standard deviation (SD) (*p,0.05) of three independent experiments. (C) Brightfield images of
representative wt and p130Tg organoids at 5 days of culture treated with ICI 182,780 and stimulated with EGF or EGF+E2 every other day. Images are
representative of three independent experiments. (D) Quantification of primary and secondary branching of wt vs. p130Tg organoids at 5 days of
culture treated with ICI 182,780 and stimulated with EGF or EGF+E2 of three independent analyses. Two-way ANOVA analysis show a significant effect
of both treatment (EGF vs. EGF+E) and genotype (wild type vs. transgenic) for Acinar Structures, primary and secondary branching (P,0.0001 for both
treatment and genotype). Interaction between treatment and genotype is significant for all variables (all P,0.0001).
doi:10.1371/journal.pone.0049817.g006
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signals [22]. By antagonizing ER and by inhibition of EGFR
activity, we were able to demonstrate that p130Cas affects the
morphogenetic outcome by modulating the MAPK activation
levels. Specifically, the treatment with the ER antagonist ICI
182,780 was able to rescue mammary branching in p130Tg
organoids. Moreover, our data indicate that in presence of
p130Cas, upon the concomitant treatment with EGF and E2, Akt
activation is enhanced with respect to EGF alone and to wt
organoids, thus underlining the role of p130Cas in promoting an
additive effect of EGF and E2 stimulation on Akt activation.
Therefore, these results suggest that p130Cas might be able to
converge signals coming from different stimuli on downstream
effector molecules thus leading to their abnormal activation.
It is now well accepted that E2 induces cellular effects
independently on ER transcriptional activity both in vivo and in
vitro [34,35,36]. These so-called non genomic signals are rapidly
activated within seconds to minutes and involve the activation of
several signal transduction pathways, such as MAPKs or PI3K/
Akt in E2-sensitive cells [37,38]. E2-dependent activation of Erk1/
2 MAPKs appears to be conserved among a variety of cell lines
[39]. In addition, it is emerging that different growth factor
receptors, including EGFR, can behave as cell-specific docking
sites for E2-activated ER alpha, setting up the basis for the
existence of a cross-talk between ER and growth factor receptor
signaling [40,41,42,43]. It has been proposed that the mechanisms
underlining the estrogen and growth factor receptor cross-talk can
be the result of the rapid translocation of ER to the cell
membrane, membrane ruffles, and pseudopodia [42,44,45].
Membrane-associated and cytoplasmic proteins have also been
shown to be important in facilitating ER localization to the plasma
membrane and to integrate ER extra-nuclear signaling with other
membrane/cytoplasmic signaling pathways. Moreover, the pres-
ence of extra-nuclear ER has been suggested to be required in
order to mediate E2-induced Erk1/2 MAPK and activation and
anti-apoptotic effects in osteoblasts [46]. In addition, it has been
reported that extra-nuclear ERalpha upon E2 stimulation can
trigger the activation of PI3K by interacting with its regulatory
subunit, leading to downstream kinase Akt activation and
promoting survival and proliferative pathways [47] Therefore,
we can envisage a scenario in which p130Cas-dependent increased
survival and MAPK activation observed upon E2 and EGF
stimulation might be due at least in part to p130Cas-dependent
induction of ER non genomic signaling that synergize on EGFR
downstream signaling to MAPKs and Akt.
Finally, it is worth noting that early premalignant breast cancer
lesions, such as hyperplastic lesions with atypia and carcinoma in
situ, are characterized by a complete or partially filled lumen and
that increased signaling through the Erk1/2 MAPKs pathway has
been implicated in several types of human breast cancer and in
many experimental models of cancer progression [25]. Very little
is known about the molecular mechanisms that disrupt normal
ductal organization of epithelial cells and understanding these
molecular mechanisms may provide new insights on the events
that regulate initiation of cancer, and lead to the identification of
both molecular markers and drug targets for premalignant disease.
Our data clearly indicate that p130Cas up-regulation is implicated
in both luminal filling and in tempering Erk1/2 MAPKs levels of
activation; two events considered hallmarks of cancer initiation,
suggesting that p130Cas over-expression might serve as a bona
fide prognostic molecular marker for early breast cancer lesions.
Supporting Information
Figure S1 p130Cas over-expression by itself does not
affect branching morphogenesis and its expression in wt
organoids is not altered upon different stimuli. (A)
Brightfield images of representative wt and p130Tg untreated
organoids after 1, 4 and 5 days in the culture medium. (B)
p130Cas protein expression does not change upon stimulation
with EGF, E2 or EGF+E2.
(TIF)
Figure S2 E2 treatment of p130Tg organoids alters
myoepithelial-luminal architecture and lumen clear-
ance. Additional representative immunofluorescence images of
K14 (red; myoepithelium) and K18 (green; luminal epithelium)
staining of wt and p130Tg organoids stimulated with EGF and
EGF+E2 at day 5 of culture. Images were taken at 206
magnification.
(TIF)
Figure S3 p130Cas phoshorylation and expression are
not altered following ICI 182,780 and AG4178. Western
blot analysis of phospho-p130Cas (Tyr410) in untreated wt
organoids and in organoids pre-treated for 1 hour with ICI
182,780 or AG1478 followed by 5 minutes of E2, EGF or
EGF+E2 stimulation. p130Cas and vinculin blots are provided as
loading controls. Blots are representative of two independent
experiments.
(TIF)
Figure S4 Effect of the inhibition of Erk1/2 MAPK,
EGFR and ER activity in mammary branching morpho-
genesis. (A) Brightfield images of representative 5 day wt and
p130Tg cultured organoids treated with PD98059, AG1478 and
ICI 182,780 and stimulated with EGF or E2/EGF every other
day. Images are representative of three independent experiments.
(TIF)
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